Liver Imaging: Types, Reasons, and What They Diagnose

Liver imaging spans a wide range of technologies, from a quick bedside ultrasound that takes minutes to specialized MRI sequences that can map fat content down to a fraction of a percent. The imaging type your doctor orders depends on the clinical question: is it a screening check for fatty liver, a detailed look at a suspicious mass, a measure of scar tissue, or surveillance after a transplant? Each modality has strengths, blind spots, and trade-offs in cost, availability, and what it can actually tell a clinician. Understanding those differences helps you make sense of what is being ordered and why.

Ultrasound as the Starting Point

For most liver concerns, conventional ultrasound is the first imaging test ordered. It is inexpensive, widely available, involves no radiation, and can be done at the bedside. It works well for spotting structural abnormalities like cysts, gallstones, and dilated bile ducts. It is also the standard initial screening tool for fatty liver disease: when fat affects more than roughly a third of the liver, ultrasound can reliably detect it in the right clinical context.

That said, ultrasound has clear limits. It struggles with mild steatosis, where fat content is below that one-third threshold. In children with obesity, one study found that ultrasound had only about 51% sensitivity for detecting hepatic steatosis at its best scoring cutoff, meaning it missed roughly half of confirmed cases.

Ultrasound also cannot stage fibrosis on its own, so if scarring is the clinical question, other tools are needed.

In pediatric medicine, ultrasound plays an especially critical role in evaluating newborns with prolonged jaundice. Biliary atresia, a condition where bile ducts are absent or blocked, must be caught early for surgical correction to work. Ultrasound features like a non-visible gallbladder, a small gallbladder with irregular walls, or a triangular cord sign near the liver hilum are individually associated with the diagnosis. One study found that ultrasound biomarkers reached 100% sensitivity and 86% specificity for biliary atresia, and combining those findings with an elevated serum enzyme level pushed specificity above 95%.

CT Scanning for Detailed Cross-Sectional Views

Computed tomography provides fast, high-resolution images of the liver and is particularly useful when a mass needs characterization or when cancer staging is the goal. Modern multiphase CT captures the liver at different moments after contrast dye injection, because different types of lesions light up at different times. A tumor with a rich blood supply, like hepatocellular carcinoma, tends to enhance brightly during the arterial phase, while certain metastases are best seen during the portal venous phase, when the surrounding liver tissue is at peak enhancement and the lesion looks darker by comparison.

Getting the timing right matters a great deal. A study comparing patient-tailored scan delays to fixed timing found that individualizing the delay produced markedly better lesion visibility. For blood-rich lesions, the difference in contrast between the lesion and the normal liver was about 84 versus 57 units on the scan’s density scale when timing was personalized.

⁴

That gap can be the difference between catching a small tumor and missing it entirely. The trade-off with CT is radiation exposure: repeated scans add up over time, which is why CT is typically reserved for specific clinical questions rather than routine screening.

MRI and Liver-Specific Contrast Agents

MRI offers the most detailed tissue characterization of any liver imaging modality. It excels at distinguishing between different types of soft tissue and can identify lesion composition, such as whether a mass contains fat, blood products, or fibrotic tissue. What makes liver MRI especially powerful is the availability of liver-specific contrast agents. Unlike standard contrast dyes that stay in the bloodstream and wash out, gadoxetic acid is actually taken up by functioning liver cells and later excreted into the bile ducts. This creates a unique imaging phase, the hepatobiliary phase, which lights up normal liver tissue while most tumors stay dark because their cells do not absorb the contrast.

⁵

This property makes liver-specific MRI invaluable for a few problems that other imaging struggles with. One is telling benign liver masses apart. Two of the most common benign liver tumors, focal nodular hyperplasia and hepatocellular adenoma, can look similar on standard imaging but behave very differently clinically. Hepatocellular adenomas carry a small risk of bleeding or malignant transformation, while focal nodular hyperplasia is almost always harmless. On gadoxetic acid-enhanced MRI, focal nodular hyperplasia retains the contrast in the hepatobiliary phase because it contains functioning liver cells, while adenomas do not. One study found that a specific measurement of enhancement in the hepatobiliary phase was 100% specific and about 92% sensitive for identifying adenomas, with an overall accuracy above 97%.

⁶

Hepatobiliary contrast agents also allow doctors to assess the biliary system’s structure and function at the same time as evaluating liver masses, essentially combining two imaging goals in a single exam.

⁷

Measuring Liver Stiffness with Elastography

Liver fibrosis, the progressive scarring that results from chronic liver disease, has traditionally required a biopsy to stage. But biopsy is invasive, carries a small risk of bleeding, and samples only a tiny sliver of the organ. Elastography offers a noninvasive alternative by measuring how stiff the liver tissue is: more scar tissue means a stiffer liver.

Two broad categories exist. Ultrasound-based elastography, including vibration-controlled transient elastography and two-dimensional shear wave elastography, can be performed in an office visit, sometimes attached to the same ultrasound machine used for conventional imaging. MR elastography uses an MRI scanner with a special vibrating device placed on the abdomen. Multiple studies have shown a strong correlation between MR elastography-measured stiffness and the stage of fibrosis found on biopsy, and the technique is emerging as a safer, less expensive, and potentially more accurate alternative to the needle.

⁸

How do the two approaches compare? Both ultrasound-based and MR elastography are considered promising surrogate markers for fibrosis severity.

⁹

MR elastography tends to be more accurate, especially in patients with obesity where ultrasound waves can be unreliable, but it is more expensive and less accessible. In many clinical pathways, ultrasound-based elastography is used first, and MR elastography is reserved for cases where the initial result is borderline or technically unreliable.

Quantifying Liver Fat Beyond Ultrasound

When precision matters for tracking fat content over time, such as in clinical trials or in patients with metabolic liver disease, MRI-derived proton density fat fraction provides the most accurate noninvasive measurement. One study comparing this technique against a reference standard found an area under the curve of 1.00 for detecting steatosis, essentially perfect diagnostic performance. By contrast, controlled attenuation parameter, an ultrasound-based fat quantification tool often bundled with transient elastography, still performed well with an area under the curve of 0.95, but with somewhat less precision.

¹⁰

For most patients being evaluated for fatty liver in a regular clinic, this level of precision is unnecessary. But for monitoring response to a weight-loss intervention or a new drug in a trial setting, MRI fat fraction has become the de facto standard because even small changes in liver fat can be tracked reliably.

Imaging the Bile Ducts with MRCP

Magnetic resonance cholangiopancreatography, or MRCP, is a specialized MRI sequence designed to visualize the bile ducts and pancreatic duct without any contrast injection at all. It relies on the natural signal of stationary fluid, which makes bile-filled ducts appear bright against the surrounding tissue. MRCP was introduced in 1991 and has become a mainstay for evaluating biliary obstruction, particularly when the blockage is severe and the ducts above it need mapping before any intervention.

¹¹

Before MRCP, the main way to image the bile ducts in detail was endoscopic retrograde cholangiopancreatography, which involves threading a scope into the small intestine and injecting dye directly into the ducts. That procedure is still used, but primarily when an intervention is planned, such as removing a stone or placing a stent. MRCP has largely replaced it as the diagnostic step, because it gives comparable anatomical detail without the risks of sedation, perforation, or pancreatitis that come with the endoscopic approach.

¹²

Nuclear Medicine and PET Scanning

Nuclear medicine contributes to liver imaging in two main ways. The first is the HIDA scan (hepatobiliary iminodiacetic acid scan), which tracks a radioactive tracer as it is taken up by liver cells and excreted into the bile ducts, then drains into the gallbladder and small intestine. It is primarily used to assess gallbladder function and bile flow, and in pediatric patients it is one of the key tests for evaluating suspected biliary atresia. In one retrospective cohort, the HIDA scan correctly identified 20 of 21 confirmed cases of biliary atresia, though it also produced eight false positives, most of whom turned out to have neonatal hepatitis.

¹³

The second application is PET/CT, which uses a radioactive sugar or a receptor-targeting tracer to identify metabolically active tissue. In oncology, PET/CT is used to detect liver metastases from cancers elsewhere in the body. A comparison of MRI and PET/CT for detecting liver metastases from gastrointestinal and pancreaticobiliary tumors found no significant difference in the overall number of metastases detected, but MRI was better at catching small lesions under 10 mm, while PET/CT added information about metabolic activity that MRI cannot provide. The researchers concluded that combining the two modalities offered the most complete picture.

¹⁴

Liver Cancer Screening and the LI-RADS Framework

If you have cirrhosis or chronic hepatitis B, you are considered at risk for hepatocellular carcinoma, and guidelines typically recommend regular surveillance imaging. When a suspicious lesion is found, radiologists use a standardized scoring system called LI-RADS to categorize how likely it is to be cancer. LI-RADS evaluates features like size, arterial-phase enhancement, and washout patterns to assign a category ranging from definitely benign to definitely hepatocellular carcinoma.

¹⁵

An important finding from a meta-analysis of individual patient data is that the major imaging features used in LI-RADS perform consistently regardless of the specific underlying risk factor. Whether the cirrhosis stems from alcohol, hepatitis C, or metabolic disease, the same imaging criteria apply without needing modification.

¹⁶

This consistency matters because it means doctors do not need to second-guess the criteria based on what caused the liver disease in the first place.

Interventional Radiology and Image-Guided Treatment

Liver imaging does not stop at diagnosis. For patients with hepatocellular carcinoma who are not surgical candidates, interventional radiologists use imaging to guide a range of treatments directly to the tumor. Radiofrequency ablation, which uses heat delivered through a needle to destroy tumor tissue, is considered the leading thermoablative method for focal or multifocal early-stage disease that cannot be surgically removed. For larger tumors or patients with more compromised liver function, microwave ablation is often preferred because it can treat a bigger volume of tissue more efficiently.

¹⁷

Transarterial approaches deliver treatment through the liver’s blood supply. Transarterial chemoembolization, which combines chemotherapy with particles that block the tumor’s feeding artery, is the method of choice for patients with relatively preserved liver function. For tumors complicated by blood clots in the portal vein, transarterial radioembolization, which delivers tiny radioactive beads, is preferred because it does not depend on the same blood-flow dynamics.

¹⁷

Contrast Dye Safety and Kidney Concerns

Many liver imaging studies require contrast agents, and a common worry is kidney damage. The risk depends heavily on your baseline kidney function. For iodinated contrast used in CT, the risk of acute kidney injury is minimal if your kidney filtration rate is above 30 mL/min, and expert consensus holds that necessary imaging should not be delayed in patients with chronic kidney disease when the study is clinically important.

¹⁸

The risk rises meaningfully as kidney function declines. One review estimated acute kidney injury rates of roughly 5% when the filtration rate is above 60, climbing to around 30% when it drops below 30.

¹⁹

Preventive strategies like intravenous saline hydration before and after the scan can reduce this risk. For gadolinium-based contrast agents used in MRI, a condition called nephrogenic systemic fibrosis was a historical concern, but the risk with newer group II agents is considered negligible even in advanced kidney disease or dialysis patients.

¹⁸

What Happens When a Lesion Is Found by Accident

Not every liver finding comes from a scan ordered to look at the liver. CT scans done for unrelated reasons, like evaluating abdominal pain or staging a non-liver cancer, frequently turn up incidental liver lesions. The American College of Radiology has published a white paper with algorithms for managing these findings, branching the decision tree based on patient characteristics and imaging features. A small, well-defined cyst in someone with no cancer history almost never needs follow-up. A solid nodule in someone with cirrhosis requires a very different workup.

²⁰

The Canadian Association of Radiologists has endorsed and adapted these guidelines, extending them to cover incidental gallbladder findings and biliary dilatation as well.

²¹

The goal of these algorithms is to prevent two opposite problems: unnecessary invasive workups for harmless cysts and hemangiomas, and missed cancers that get dismissed as benign without proper evaluation.

Imaging After Liver Transplant

After a liver transplant, imaging surveillance follows a specific schedule. Doppler ultrasound is routinely performed within 24 to 48 hours of surgery, again at one week, and then at one and three months. The main concern in the early post-operative period is vascular complications: clotting or narrowing of the hepatic artery, portal vein problems, or obstruction of hepatic vein outflow. Doppler ultrasound is the first-line tool because it can assess blood flow in real time without contrast or radiation.

²²

When ultrasound findings are abnormal or inconclusive, contrast-enhanced CT, MRI, or even catheter angiography may follow. Biliary complications, the second major category of post-transplant problems, are evaluated with MRCP or, when intervention is needed, endoscopic retrograde cholangiopancreatography. The key takeaway for patients is that frequent imaging after transplant is normal and expected, not necessarily a sign that something has gone wrong.

²³

How Breath-Holding and Preparation Affect Your Scan

If you have ever had a liver MRI, you know it involves holding your breath multiple times, sometimes for 15 to 20 seconds per sequence. Motion artifacts from breathing can blur key details, especially during the brief arterial phase when contrast enhancement is captured. A randomized trial tested whether visualized respiratory training before the scan, essentially coaching patients with real-time feedback, improved cooperation. The trained group had a full cooperation rate of about 57% compared to 27% in the standard preparation group, with noticeably fewer motion artifacts and better image quality in the critical contrast phases. Preparation time was also shorter by almost two minutes on average.

²⁴

Practical advice: if you struggle with breath-holding, let the MRI technologist know before the scan starts. Many centers now offer brief coaching sessions, and even a few minutes of practice can meaningfully improve the images your radiologist has to work with.

AI in Liver Imaging and Where It Is Headed

Artificial intelligence is increasingly being integrated into liver imaging workflows. Segmentation models, which automatically outline the liver and its vessels on CT or MRI, can now estimate the volume of liver that would remain after a planned surgery, measure the size of a potential transplant graft, assess tumor burden, and map vascular anatomy for intervention planning.

²⁵

AI tools aligned with the LI-RADS scoring system are also being developed to help radiologists categorize liver lesions more consistently, though these remain in validation stages rather than clinical deployment for most centers.

¹⁵

Access Gaps Around the World

The imaging landscape described above reflects what is available in well-resourced healthcare systems. Globally, access is uneven. Advanced tools like transient elastography devices and acoustic radiation force impulse imaging remain largely unavailable in rural settings in many African countries due to the cost of the equipment, ongoing maintenance requirements, and the need for specialized training.

²⁶

Even ultrasound quality varies widely depending on operator experience and equipment age. Cost-effectiveness analyses suggest that regions with high rates of liver cancer mortality may benefit from investing in surveillance programs, but the choice between ultrasound-based and biomarker-based screening depends on local factors including obesity prevalence, the dominant causes of liver disease, and whether high-quality ultrasound is reliably available.

²⁷

Japan’s experience illustrates the other end of the spectrum: a comprehensive surveillance program incorporating ultrasound, biomarkers, and CT or MRI has translated into earlier cancer detection and reduced liver cancer mortality compared to regions relying on less intensive strategies.

²⁷

1
PubMed Central. Bedside ultrasound in the diagnosis of nonalcoholic fatty liver disease
2
PubMed Central. Comparison of diagnostic accuracy of screening tests ALT and ultrasound for pediatric non-alcoholic fatty liver disease
3
PubMed Central. Ultrasonographic and serum biomarkers for diagnosis of biliary atresia
4
PubMed. Patient-tailored scan delay for multiphase liver CT: improved scan quality and lesion conspicuity with a novel timing bolus method
5
PubMed. Current and Advanced Applications of Gadoxetic Acid-enhanced MRI in Hepatobiliary Disorders
6
PubMed. Characteristics and distinguishing features of hepatocellular adenoma and focal nodular hyperplasia on gadoxetate disodium-enhanced MRI
7
PubMed. Hepatobiliary MRI contrast agents: Properties, clinical applications and future directions
8
PubMed Central. Magnetic resonance elastography of liver: technique, analysis, and clinical applications
9
Clinical Gastroenterology and Hepatology. Direct Comparison of US and MR Elastography for Staging Liver Fibrosis in Patients With Nonalcoholic Fatty Liver Disease
10
Clinical Nutrition ESPEN. The diagnostic value of controlled attenuation parameter (CAP) and magnetic resonance imaging derived proton density fat fraction (MRI-PDFF) for the evaluation of intestinal failure-associated liver disease steatosis among adult chronic intestinal failure patients
11
PubMed Central. Role of magnetic resonance cholangiopancreatography in the evaluation of biliary disease
12
International Journal of Hepatobiliary and Pancreatic Diseases. Application of magnetic resonance cholangiopancreatography and endoscopic retrograde cholangiopancreatography in biliary obstruction
13
PubMed Central. Hepatobiliary Iminodiacetic Acid (HIDA) Scan in the Evaluation of Biliary Atresia: A Retrospective Cohort Study
14
PubMed Central. Comparison of MRI and 18F-FDG PET/CT in the Liver Metastases of Gastrointestinal and Pancreaticobiliary Tumors
15
PubMed. LI-RADS-aligned artificial intelligence for liver cancer diagnosis: methods, evidence, and clinical readiness
16
PubMed. Do Risk Factors for HCC Impact the Association of CT/MRI LIRADS Major Features With HCC? An Individual Participant Data Meta-Analysis
17
PubMed Central. The role of interventional radiology in the management of hepatocellular carcinoma
18
Journal of the Formosan Medical Association. Use of iodinated and gadolinium-based contrast media in patients with chronic kidney disease
19
PubMed Central. Key Considerations regarding the Renal Risks of Iodinated Contrast Media: The Nephrologist’s Role
20
PubMed. Management of Incidental Liver Lesions on CT: A White Paper of the ACR Incidental Findings Committee
21
PubMed. Recommendations for the Management of Incidental Hepatobiliary Findings in Adults
22
PubMed Central. Role of imaging in the evaluation of vascular complications after liver transplantation
23
PubMed. Multimodality Imaging after Liver Transplant: Top 10 Important Complications
24
Journal of Magnetic Resonance Imaging. Effect of Visualized Respiratory Training on Patient Cooperation and Image Quality in Gadoxetic Acid Disodium-Enhanced Liver MRI: A Randomized Controlled Trial – Section: RESULTS
25
PubMed Central. Advances in Artificial Intelligence‐Based Liver‐Related Semantic Segmentation Techniques and Applications Using CT Imaging
26
PubMed Central. Liver disease diagnostics and access barriers in African settings: a narrative review
27
PubMed Central. Cost-Effectiveness of a Biomarker-Based Screening Strategy for Hepatocellular Carcinoma in Patients with Cirrhosis